Drug intelligence / Profile preview

ELU530

Development stage: Preclinical
Lead developer: Eluciderm
Modality: Small Molecules
Administration: Topical

Overview

ELU530 is a preclinical-stage small molecule therapeutic developed by Eluciderm for the topical treatment of inflammatory skin diseases, specifically psoriasis and atopic dermatitis. The compound is part of a platform focused on modulating the Wnt signaling pathway to stimulate the body's natural regenerative mechanisms. By utilizing a topical route of administration, ELU530 aims to provide localized treatment for chronic skin conditions while minimizing systemic exposure and potential side effects associated with systemic therapies.

Beyond the preview

Go deeper on ELU530.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELU530.

Explore the full profile